What are the diagnostic criteria, recommended surveillance strategies, treatment options, and prognosis for primary vitreoretinal lymphoma?

Primary Vitreoretinal Lymphoma: Comprehensive Clinical Management

Diagnostic Criteria

Diagnosis of PVRL requires vitrectomy with comprehensive tissue analysis including conventional cytology, flow cytometry, and molecular testing—specifically MYD88 L265P mutation and IL-10 levels in vitreous or aqueous humor. 1

Essential Diagnostic Components:

Vitreous/Aqueous Sampling:

• Conventional cytology examination (mandatory)
• Flow cytometry when possible
• MYD88 L265P mutation analysis (highly supportive though not diagnostic alone)
• IL-10 level measurement (IL-10/IL-6 ratio >1 strongly suggests lymphoma)
• IgVH clonality assessment in selected cases 1

Clinical Features Raising Suspicion:

• Vitreous opacity (present in ~90% of cases) 2
• Subretinal/sub-RPE infiltrates (45% of cases)
• Bilateral or asymmetric involvement
• Partial steroid responsiveness (a key masquerade feature) 3

Multimodal Imaging Findings:

• OCT: Vitreous opacity (79.68%), RPE-Bruch's membrane infiltration (43.46%), RPE hyperreflective material (45.56%), fuzzy outer retina (39.32%), subretinal hyperreflective material (39.68%) 2
• Fundus autofluorescence: Hyper-autofluorescent lesions (75.5% prevalence) 2
• Fluorescein angiography: Leopard spots (51.2%), multiple hypofluorescent spots (40.6%) 2

Mandatory CNS Evaluation:

• Contrast-enhanced brain MRI (3T or 1.5T using IPCG protocol) 1
• CSF analysis if clinically indicated
• This is critical because PVRL has high risk of CNS dissemination

Critical Pitfall:

Avoid corticosteroids before tissue biopsy whenever clinically possible 1. Steroids can cause lymphoma regression, leading to false-negative biopsies and diagnostic delay.

---

Treatment Approach

Fit patients with PVRL should receive high-dose methotrexate (HD-MTX)-based systemic chemotherapy using the same regimens as for PCNSL, with intravitreal methotrexate added when rapid intraocular disease control is needed. 1

First-Line Treatment Algorithm:

For Fit Patients (no major comorbidities, good performance status):

1. Induction: HD-MTX-based polychemotherapy (same combinations as PCNSL)

   • Add intravitreal MTX injections if rapid regression of intraocular disease needed 1

2. Consolidation (for patients achieving CR or PR):

   • Low-dose bilateral ocular radiotherapy 1
   • OR discuss risks/benefits of autologous stem cell transplantation (ASCT) in selected patients 1

Rationale: While local treatments alone control intraocular disease, they fail to prevent CNS relapses. A retrospective study of 59 patients showed median survival without brain relapse of 73 months with HD-MTX-based chemotherapy, and zero intraocular relapses in patients receiving additional local treatment at 5-year follow-up 1.

For Unfit Patients or Contraindications to Chemotherapy:

• Oral temozolomide (not FDA/EMA approved for this indication) 1
• OR local therapies: ocular radiotherapy or intravitreal MTX injection 1

Relapsed/Refractory Disease:

Fit patients with r/r PVRL:

• Second-line chemotherapy followed by consolidative high-dose chemotherapy with ASCT 1

Unfit patients with r/r PVRL:

• Local treatments (ocular RT or intravitreal MTX)
• OR ibrutinib, lenalidomide (±rituximab), or temozolomide 1
• Note: These targeted agents are not FDA/EMA approved but show activity in r/r PVRL

Important Treatment Considerations:

The 2015 European collaborative study of 78 patients showed that systemic chemotherapy did not definitively prevent CNS involvement (CNSL developed in 32-43% across all treatment groups), but this older data predates modern HD-MTX regimens 4. More recent evidence from the 2024 EHA-ESMO guidelines supports upfront systemic treatment to reduce brain relapse risk 1.

---

Surveillance Strategy

Follow-up imaging with ophthalmological examination should occur at 3-month intervals for the first 2 years, then every 6 months for years 3-5, then annually thereafter. 1

Structured Surveillance Protocol:

Ophthalmological Monitoring:

• Slit lamp and fundus examination during and after induction, and after consolidation 1
• Annual ophthalmological examination if eyes not initially involved
• More frequent examination if eyes initially involved or with visual deterioration 1

Response Assessment Tools:

• Clinical examination (though precise response definition is difficult)
• MYD88 L265P and IL-10 levels in aqueous humor (useful to monitor intraocular response when available) 1
• Optical coherence tomography and angiography (improve response definition) 1
• Post-treatment OCT typically shows decreased subretinal hyperreflective material, PED, subretinal fluid, and retinal hyperreflectivity 2

CNS Surveillance:

• Brain MRI: Every 3 months for 2 years, then every 6 months for years 3-5, then annually 1
• CSF assessment: Only in cases of suspected or confirmed relapse 1

Quality of Life Monitoring:

• Neurocognitive function and QoL assessment annually (at minimum within clinical trials) 1

Key Surveillance Principle:

Only 20% of relapses are diagnosed on surveillance imaging; most present with rapid progression and neurological symptoms 1. However, surveillance remains critical for patients eligible for intensive salvage therapies.

---

Prognosis

The prognosis of PVRL remains poor, with CNS involvement developing in approximately 36% of patients at median follow-up of 49 months, and 5-year survival significantly worse in those who develop CNS disease (35% vs 68%). 4

Prognostic Factors:

CNS Involvement is the Critical Determinant:

• 5-year cumulative survival: 35% with CNS involvement vs 68% without CNS involvement (P=0.003) 4
• CNS dissemination occurs in 32-43% of patients regardless of initial treatment strategy 4
• Median survival without brain relapse with HD-MTX chemotherapy: 73 months 1

Timing of Relapse Matters:

• Patients with relapse after 3 years: 2-year survival rate of 70%
• Patients with refractory disease: 2-year survival rate of 11%
• Patients with relapse in years 2-3: 2-year survival rate of 12% 1

Treatment Response:

• Most relapses (80%) present with rapid disease progression and neurological symptoms 1
• Relapses occur predominantly in CNS, often distant from primary lesion 1
• Less than 5% of relapses occur outside CNS 1

Realistic Expectations:

Despite therapeutic advances, 16-26% of patients are primary refractory to HD-MTX-based chemotherapy, and an additional 25% experience relapse after initial response 1. The prognosis remains "dismal" per multiple sources 5, emphasizing the need for aggressive upfront treatment and close surveillance.

Emerging Therapies:

CAR-T cell therapy targeting CD19 has shown encouraging preliminary results in r/r PCNSL (6/12 patients achieved CR in phase I/II trial), warranting further investigation for PVRL 1. However, this remains investigational.